Vyndaqel

Chemical Nametafamidis meglumine
Dosage FormCapsule (oral; 20 mg)
Drug ClassMiscellaneous
SystemCardiovascular
CompanyFoldRx Pharmaceuticals
Approval Year2019

Indication

  • Vyndaqel is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Last updated on 10/20/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?